DOCSLIB.ORG

Medications Used for the Treatment of Cardiovascular Disease Page E-1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medications Used for the Treatment of Cardiovascular Disease Page E-1 WHI - Volume 8, Appendix E – Medications Used For The Treatment of Cardiovascular Disease Page E-1 APPENDIX E MEDICATIONS USED FOR TREATMENT OF CARDIOVASCULAR DISEASE E.1 Medications Used for the Treatment of Congestive Heart Failure Product Name Generic Name Drug Class Accupril Quinapril Hydrochloride ACE inhihibitor Alazide Spironolactone and Diuretic Hydrochlorothiazide Alazine Hydralazine Hydrochloride Vasodilator Aldactazide Spironolactone & Diuretic Hydrochlorothiazide Aldactone Spironolactone Diuretic Aldoclor Chlorothiazide & Methyldopa Vasodialator/diuretic combination Aldomet Methyldopa Vasodilator Aldoril/Aldoril-D Hydrochlorothiazide & Methyldopa Vasodilator/diuretic combination Alpha-Methyldopa Methyldopa Vasodilator Altace Ramipril ACE inhibitor Amiloride Hydrochloride Amiloride Hydrochloride Diuretic Apo-guanethidine Guanethidine Sulfate Vasodilator Apresazide Hydralazine Hydrochloride & Vasodilator/diuretic combination Hydrochlorothiazide Apresex Hydralazine Hydrochloride Vasodilator Apresodex Hydralazine Hydrochloride & Vasdodilator/diuretic combination Hydrochlorothiazide Apresoline Hydralazine Hydrochloride Vasodilator Apresoline-Esidrex Hydralazine Hydrochloride & Vasodilator/diuretic combination Hydrochlorothiazide Aprozide Hydralazine Hydrochloride & Vasodilator/diuretic combination Hydrochlorthiazide Aquapres Benzthiazide Vasodilator/diuretic combination Aquatag Benzthiazide Diuretic Aquatensen Methyclothiazide Diuretic Benazepril Hydrochloride Benazepril Hydrochloride ACE inhibitor Bendroflumethiazide Bendroflumethiazide Diuretic Benzthiazide Benzthiazide Diuretic Bumetanide Bumetanide Diuretic Bumex Bumetanide Diuretic Cam-ap-es Hydrochlorothiazide, Reserpine & Vasodilator/diuretic combination Hydralazine Hydrochloride R:\DOC\MAN\CUR\VOL8\E.DOC WHI MANUALS: VOLUME 8 - OUTCOMES VER. 1: 08/15/97 WHI - Volume 8, Appendix E – Medications Used For The Treatment of Cardiovascular Disease Page E-2 Product Name Generic Name Drug Class Capoten Captopril ACE inhibitor Capozide Captopril & Hydrochlorothiazide ACE inhibitor/diuretic combination Captropril Captopril ACE inhibitor Catapres Clonidine Hydrochloride Vasodilator Cerespan Papaverine Hydrochloride Vasodilator Chloroserpine Chlorothiazide & Reserpine Vasodilator Chlorothiazide Chlorothiazide Diuretic Chlorthalidone Chlorthalidone Diuretic Clandelate Cyclandelate Vasodilator Clonidine Hydrochloride Clonidine Hydrochloride Vasodilator Combipres Chlorthalidone & Clonidine Vasodilator/diuretic combination Hydrochloride Cozaar Losartan Potassium Vasodilator Cozaar Losartan Potassium Vasodilator Crystodigin Digitoxin Digitalis Cyclan Cyclandelate Diuretic Cyclandelate Cyclandelate Vasodilator Cyclospasmol Cyclandelate Vasodilator Demadex Porsemide Diuretic Demi-Regroton Chlorthalidone & Reserpine Vasodilator/diuretic combination Diachlor Chlorothiazide Diuretic Diaqua Hydrochlorothiazide Diuretic Digitoxin Digitoxin Digitalis Digoxin Digoxin Digitalis Diucardin Hydroflumethazide Diuretic Diulo Metolazone Diuretic Diupres Chlorothiazide & Reserpine Vasodilator/diuretic combination Diurese Trichlormethiazide Diuretic Diurigen with Reserpine Chlorothiazide & Resperine Vasodilator/diuretic combination Diuril Chlorothiazide Diuretic Diutensin-R Methyclothiazide & Resperine Vasodialator/diuretic combination Dixaril Clonidine Hydrochloride Vasodilator Durctic Methyclothiazide Diuretic Dyazide Triamterene & Hydrochlorothiazide Diuretic Dyrenium Triamterene Diuretic R:\DOC\MAN\CUR\VOL8\E.DOC WHI MANUALS: VOLUME 8 - OUTCOMES VER. 1: 08/15/97 WHI - Volume 8, Appendix E – Medications Used For The Treatment of Cardiovascular Disease Page E-3 Product Name Generic Name Drug Class Edecrin Ethacrynic Acid Diuretic Enalapril Maleate Enalapril Maleate ACE inhibitor Enduron Methyclothiazide Diuretic Enduronyl Methyclothiazide & Deserpidine Vasodilator/diuretic combination Esidrix Hydrochlorothiazide Diuretic Esimil Guanethidine Monosulfate & Vasodilator/diuretic combination Hydrochlorothiazide Ethacrynic Acid Ethacrynic Acid Diuretic Ethaquin Ethaverine Hydrochloride Vasodilator Ethatab Ethaverine Hydrochloride Vasodilator Ethaverine Hydrochloride Ethaverine Hydrochloride Vasodilator Ethavex-100 Ethaverine Hydrochloride Vasodilator Ethon Methyclothiazide Diuretic Exna Benzthiazide Diuretic Fosinopril Fosinopril ACE inhibitor Furosemide Furosemide Diuretic Genabid Papaverine Hydrochloride Vasodilator Guanabenz Acetate Guanabenz Acetate Vasodilator Guanabenz Hydrochloride Quantacine Hydrochloride Vasodilator Guanadrel Sulfate Guanadrel Sulfate Vasodilator Guanethidine Sulfate Guanethidine Sulfate Vasodilator H.H.R. Hydralazine Hydrochloride, Vasodilator/diuretic combination Hydrochlorothiazide, & Reserpine HCTZ Hydrocholorothiazide Diuretic Hydralazine/Hydrochloride Hydralazine Hydrochloride Vasodilator Hydralazine/Hydrochlorothiazide Hydralazine Hydrochloride & Vasodilator/diuretic combination Hydrochlorothiazide Hydrazide Hydralazine Hydrochloride & Vasodilator/diuretic combination Hydrochlorothiazide Hydrex Benzthiazide Diuretic Hydro-Chlor Hydrochlorothiazide Diuretic Hydrochlorothiazide Hydrochlorothiazide Diuretic Hydrochlorothiazide/Amiloride Hydrochlorothiazide & Amiloride Diuretic Hydrochlorothiazide/Captopril Hydrochlorothiazide & Captopril Diuretic/ACE inhibitor combination Hydrochlorothiazide/Deserpidine Hydrochlorothiazide & Deserpidine Vasodilator/diuretic combination Hydrochlorothiazide/Lisonopril Hydrochlorothiazide & Lisonopril Diuretic R:\DOC\MAN\CUR\VOL8\E.DOC WHI MANUALS: VOLUME 8 - OUTCOMES VER. 1: 08/15/97 WHI - Volume 8, Appendix E – Medications Used For The Treatment of Cardiovascular Disease Page E-4 Product Name Generic Name Drug Class Hydrochlorothiazide/Reserpine Hydrochlorothiazide & Reserpine Vasodilator/diuretic combination Hydrochlorothiazide/Spironolactone Hydrochlorothiazide & Diuretic Spironolactone Hydrochlorothiazide/Triamterene Hydrochlorothiazide & Triamterene Diuretic HydroDiuril Hydrochlorothiazide Diuretic Hydroflumethiazide Hydroflumethiazide Diuretic Hydromal Hydrochlorothiazide Diuretic Hydromox Quinethazone and Reserpine Diuretic Hydropres Hydrochlorothiazide & Reserpine Vasodilator/diuretic combination Hydro-Ride Amiloride & Hydrochlorothiazide Diuretic Hydro-Serp Hydrochlorothiazide & Reserpine Vasodilator/diuretic combination Hydroserpine Hydrochlorothiazide & Reserpine Vasodilator/diuretic combination Hydrosine Hydrochlorothiazide and Reserpine Vasodilitator/diuretic combination Hydro-T Hydrochlorothiazide Diuretic Hygroton Chlorthalidone Diuretic Hylidone Chlorthalidone Diuretic Hylorel Guanadrel Sulfate Vasodilator Hyzaar Losartan Potassium & Vasodilitator/diuretic combination Hydrochlorothiazide Indapamide Indapamide Diuretic Inversine Mecamylamine Hydrochloride Vasodilator Ismelin Guanethidine Sulfate Vasodilator Isovex Ethaverine Hydrochloride Vasodilator Isoxsuprine Hydrochloride Isoxsuprine Hydrochloride Vasodilator Lanoxicaps Digoxin Digitalis Lanoxin Digoxin Digitalis Lanoxinped Digoxin Digitalis Lasix Furosemide Diuretic Lisinopril Lisinopril ACE inhibitor Lisinopril/Hydrochlorothiazide Lisinopril & Hydrochlorothiazide ACE inhibitor/diuretic combination Lo-Aqua Furosemide Diuretic Loniten Minoxidil Vasodilator Losartan Potassium Losartan Potassium Vasodilator Lotensin Benazepril Hydrochloride ACE inhibitor Lozol Indapamide Diuretic Manoplax Flosequinan Vasodilator R:\DOC\MAN\CUR\VOL8\E.DOC WHI MANUALS: VOLUME 8 - OUTCOMES VER. 1: 08/15/97 WHI - Volume 8, Appendix E – Medications Used For The Treatment of Cardiovascular Disease Page E-5 Product Name Generic Name Drug Class Marazide Benzthiazide Diuretic Maxzide Triamterene & Hydrochlorothiazide Diuretic Mecamylamine Hydrochloride Mecamyline Hydrochloride Vasodilator Metahydrin Trichlormethiazide Diuretic Metatensin Trichlormethiazide & Reserpine Vasoldilator/diuretic combination Methyclothiazide Methyclothiazide Diuretic Methyclothiazide/Deserpidine Methyclothiazide & Deserpidine Vasodilator/diuretic combination Methyldopa Methyldopa Vasodilator Metolazone Metolazone Duiretic Midamor Amiloride Hydrochloride Diuretic Minipress Prazosin Hydrochloride Vasodilator Minizide Polythiazide & Prazosin Vasodilator Hydrochloride Minoxidil Minoxidil Vasodilator Moduretic Amiloride & Hydrochlorothiazide Diuretic Moekipril HCL Moexipril Ace-inhibitor Monopril Fosinopril ACE inhibitor Mykrox Metolazone Diuretic Naqua Trichlor Methiazide Diuretic Naturetin Bendroflumethiazide Diuretic Niazide Trichlor Methiazide Diuretic Novothalidone Chlorthalidone Diuretic Oretic Hydrochlorothiazide Diuretic Oreticyl Hydrochlorothiazide & Deserpidine Vasodilator/diuretic combination Papaverine Hydrochloride Papaverine Hydrochloride Vasodilator Pavabid Papaverine Hydrochloride Vasodilator Pavagen Papaverine Hydrochloride Vasodilator Pavased Papaverine Hydrochloride Vasodilator Pavaspan Papaverine Hydrochloride Vasodilator Pavasule Papaverine Hydrochloride Vasodilator Pavatyme Papaverine Hydrochloride Vasodilator Paverolan Papaverine Hydrochloride Vasodilator Polythiazide Polythiazide Diuretic Prazosin Hydrochloride Prazosin Hydrochloride Vasodilator Prinivil Lisinopril ACE inhibitor R:\DOC\MAN\CUR\VOL8\E.DOC WHI MANUALS: VOLUME 8 - OUTCOMES VER. 1: 08/15/97 WHI - Volume 8, Appendix E – Medications Used For The Treatment of Cardiovascular Disease Page E-6 Product Name Generic Name Drug Class Prinzide Lisinopril & Hydrochlorothiazide ACE inhibitor/diuretic combination Proaqua Benzthiazide Diuretic Quinapril Hydrochloride Quinapril Hydrochloride ACE inhibitor Ramipril Ramipril ACE inhibitor Raudixin
Load more

Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/401 (2006.01) A61P 9/12 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/405 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/7048 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US20 13/039904 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 7 May 2013 (07.05.2013) NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (26) Publication Language: English ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/644,134 8 May 2012 (08.05.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (72) Inventors; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicants : STEIN, Emily A.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • DOCUMENT RESUME ED 303 441 SP 030 865 TITLE Detection
    DOCUMENT RESUME ED 303 441 SP 030 865 TITLE Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Committee. INSTITUTION National Heart, Lung, and Blood Inst. (DHHS/NIH), Bethesda, MD. PUB DATE 88 NOTE 64p. PUB TYPE Guides - Non-Classroom Use (055) EDRS PRICE MF01/PC03 Plus Postage. DESCRIPTORS *Cardiovascular System; Clinical Diagnosis; *Drug Therapy; *Hypertension; *Pharmacology; Physical Examinations; Physical Health; *Physical Therapy ABSTRACT The availability of an increased variety of therapeutic approaches provides the opportunitl to improve hypertension control while minimizing adverse effects that may influence cardiovascular complications and adherence to therapy. This report serves two purposes: (1) to guide practicing physicians and other health professionals in their care of hypertensive patients; and (2) to guide health professionals participating in the many community high blood pressure control programs. Contents include: (1) definition and prevalence of high blood pressure; (2) detection, confirmation and referral; (3) evaluation and diagnosis; (4) treatment--nonpharmacologic and pharmacologic therapy, and long-term maintenance of therapy; (5) considerations in individual therapy; and (6) special populations and management problems. Fifty-five references are included. (JD) *********************************************************************** Reproductions supplied by EDRS are the best that can be made from the original document. ************************************-*********************************
    [Show full text]
  • Initial Medication Selection for Treatment of Hypertension in an Open-Panel HMO
    J Am Board Fam Pract: first published as 10.3122/jabfm.8.1.1 on 1 January 1995. Downloaded from Initial Medication Selection For Treatment Of Hypertension In An Open-Panel HMO Micky jerome, PharmD, MBA, George C. Xakellis, MD, Greg Angstman, MD, and Wayne Patchin, MBA Background: During the past 25 years recommendations for treating hypertension have evolved from a stepped-care approach to monotherapy or sequential monotherapy as experience has been gained and new antihypertensive agents have been introduced. In an effort to develop a disease management strategy for hypertension, we investigated the prescribing patterns of initial medication therapy for newly treated hypertensive patients. Methods: We examined paid claims data of an open-panel HMO located in the midwest. Charts from 377 patients with newly treated hypertension from a group of 12,242 hypertenSive patients in a health insurance population of 85,066 persons were studied. The type of medication regimen received by patients newly treated for hypertension during an 18-month period was categorized into monotherapy, sequential monotherapy, stepped care, and initial treatment with multiple agents. With monotherapy, the class of medication was also reported. Associations between use of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, or (3-blockers and presence of comorbid conditions were reported. Results: Fifty-five percent of patients received monotherapy, 22 percent received stepped care, and 18 percent received sequential monotherapy. Of those 208 patients receiving monotherapy, 30 percent were prescribed a calcium channel blocker, 22 percent an ACE inhibitor, and 14 percent a f3-blocker. No customization of treatment for comorbid conditions was noted.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Long Acting, Reversible Veterinary Sedative and Analgesic And
    University of Kentucky UKnowledge Veterinary Science Faculty Patents Veterinary Science 7-11-2006 Long Acting, Reversible Veterinary Sedative and Analgesic and Method of Use Thomas Tobin University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/gluck_patents Part of the Veterinary Medicine Commons Recommended Citation Tobin, Thomas, "Long Acting, Reversible Veterinary Sedative and Analgesic and Method of Use" (2006). Veterinary Science Faculty Patents. 14. https://uknowledge.uky.edu/gluck_patents/14 This Patent is brought to you for free and open access by the Veterinary Science at UKnowledge. It has been accepted for inclusion in Veterinary Science Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. US007074834B2 (12) United States Patent (10) Patent N0.: US 7,074,834 B2 Tobin (45) Date of Patent: Jul. 11, 2006 (54) LONG ACTING, REVERSIBLE VETERINARY 4,742,054 A 5/1988 Naftchi SEDATIVE AND ANALGESIC AND METHOD 4,950,648 A 8/1990 Raddatz et a1. OF USE 5,635,204 A * 6/1997 GevirtZ et a1. ............ .. 424/449 5,942,241 A 8/1999 Chasin et a1. (75) Inventor: Thomas Tobin, Lexington, KY (US) 5,958,933 A 9/1999 Naftchi (73) Assignee: University of Kentucky Foundation, OTHER PUBLICATIONS Lexington, KY (US) MEDLINE AN 20000025586, Veveris et al, Brit. J. Pharmacol, 128 (5), 1089-97, Nov. 1999, abstract.* ( * ) Notice: Subject to any disclaimer, the term of this Veterinary Pharmacology and Therapeutics, Adams, pp.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://edhub.ama-assn.org/ on 09/24/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]